Stem Cells Spin (WAR:SCS) EBIT: zł-0.55 Mil (TTM As of Mar. 2026)


WAR:SCS Stem Cells Spin SA WAR:SCS
25 GF Score
Price zł0.40
GF Value zł0.10
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Stem Cells Spin EBIT?

Stem Cells Spin WAR:SCS 25 EBIT is zł-0.55 Mil as of Mar. 2026. GuruFocus rates WAR:SCS with a GF Score™ of 25/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Stem Cells Spin's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was zł-0.17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was zł-0.55 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Stem Cells Spin's annualized ROC % for the quarter that ended in Mar. 2026 was -7.26%. Stem Cells Spin's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -131.24%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Stem Cells Spin's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3.32%.


Stem Cells Spin  (WAR:SCS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Stem Cells Spin's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-0.668 * ( 1 - 0% )/( (9.391 + 9.017)/ 2 )
=-0.668/9.204
=-7.26 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Stem Cells Spin's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.668/( ( (0.01 + max(0.5, 0)) + (0.009 + max(0.499, 0)) )/ 2 )
=-0.668/( ( 0.51 + 0.508 )/ 2 )
=-0.668/0.509
=-131.24 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.013 + 0.597 + 0.004) - (0.107 + 0 + 0.007)
=0.5

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.014 + 0.605 + 0.006) - (0.111 + 0 + 0.015)
=0.499

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Stem Cells Spin's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-0.551/16.619
=-3.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stem Cells Spin EBIT Related Terms


Stem Cells Spin EBIT Historical Data

* Premium members only.

The historical data trend for Stem Cells Spin's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stem Cells Spin EBIT Chart

Stem Cells Spin Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 0.03 -0.15 -0.52 -0.52

Stem Cells Spin Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 -0.12 -0.12 -0.15 -0.17

WAR:SCS vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Stem Cells Spin's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stem Cells Spin EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stem Cells Spin's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Stem Cells Spin's EV-to-EBIT falls into.


WAR:SCS
25GF Score
Stem Cells Spin SA WAR:SCS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stem Cells Spin EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of zł-0.55 Mil mean?
Stem Cells Spin (WAR:SCS) has a EBIT of zł-0.55 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Stem Cells Spin.
Is Stem Cells Spin's EBIT too high?
Stem Cells Spin's current EBIT is zł-0.55 Mil. Overall, Stem Cells Spin has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's EBIT compare to VRTX and REGN?
Stem Cells Spin's EBIT of zł-0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Stem Cells Spin. Stem Cells Spin's current EBIT is zł-0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.40 — trading 300% above its estimated fair value. The current EBIT is zł-0.55 Mil. Stem Cells Spin's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current EBIT is zł-0.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?

Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued. The current stock price of zł0.40 is trading 300% above its estimated GF Value™ of zł0.10. GuruFocus considers Stem Cells Spin to be Significantly Overvalued.

Key valuation signals for WAR:SCS:

  • EBIT: zł-0.55 Mil
  • GF Value™: zł0.10 vs. price of zł0.40 (300% above fair value)
  • GF Score™: 25/100 with 3 warning signs

No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Stem Cells Spin Business Description

Address Ulica Konopnickiej 15 b, Wroclaw, POL, 51-141
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
25GF Score

Get the complete analysis for WAR:SCS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.40
Price
zł0.10
GF Value